Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMengjie DingFNFeifei Nan

Discussion

Loading...

Member takes

Overview

Real-world analysis shows CAR T cell therapy improved complete response and progression-free survival in high-risk B-cell lymphoma patients, implying effective consolidation after first-line treatment

Key Points

  • This study examines the efficacy and safety of CAR T cell therapy as a consolidation treatment in high-risk B-cell lymphoma patients.
  • Real-world case series study
  • Enrolled patients with B-cell lymphoma treated with CAR T cell therapy after achieving response to 1L treatment
  • Evaluated complete metabolic response, overall survival, and progression-free survival rates
  • Achieved 100% complete metabolic response after CAR T cell therapy
  • Both 18-month overall survival and progression-free survival rates were 100%
  • All patients experienced mild cytokine release syndrome without severe adverse events

Cite This Study

Ding et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc33https://doi.org/10.1182/blood-2025-8015
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term real-world outcomes of axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).2026
  2. 2Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience2025
  3. 3Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017 · 6,103 citations
  4. 4Outcomes of second‐line axicabtagene ciloleucel for large B‐cell lymphoma in the UK2026 · 2 citations
  5. 5Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel2025